Clinical trials using EGFR inhibitors such as Cetuximab (IMC-C225) have shown encouraging activity both as a monotherapy as well as in combination with either chemotherapy or radiation, including patients with head and neck squamous cell carcinoma, non-small-cell lung cancer and colorectal cancer (Rubin et al, 2000; Saltz et al, 2002). Here, EGFR is linked to non-small cell lung carcinoma.